


# Phase II Committee (Kohn/Mirza)

---




**Open studies reviewed and progress noted; no new concepts.**

- **Ov: NRG GY005 phase 2; AVANOVA; AVANOVA-Immune1; STICs & STONEs; NEO; eVOLVE, OLALA**
- **EN2: FANDANGO; PALEO; UMB1; MaRuC**

**Discussion GTAC**

**Review of Committee Goals**

# GTAC: GCIIG-wide Targeted therapy Against Cervical cancer



**NSGO: Niraparib v placebo**

**GEICO: TSR-042 v obs**

**PMHC: just approved**

**Discussion: modify eligibility with harmonized criteria--**

- include PR stratified with III/IVA, PALN+
- Harmonize 12 week assessment (MRI or PET/CT and clinical, no bx)



## PHASE 2 COMMITTEE

### GOALS:

- **Advancing new opportunities through collaborative phase 2 multi-group studies**
- **Fostering communication regarding early phases study results to inform of new opportunities**
- **Collaborate with site committees in focused development**
- **Collaborate with Rare Tumors committee where phase 2 studies may be the target**
- **Moving GTAC forward**